Please assess the completion status of the following clinical trial:

Trial Title: CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to provide written informed consent~* Able and willing to complete all protocol requirements~* Between 18 to 65 years of age~* Presence of persistent asthma for at least 6 months according to GINA 2011 guidelines at step 3 or 4 of treatment who has been on stable controller therapy for at least 4 weeks, and symptoms are not sufficiently controlled with medium to high doses of inhaled corticosteroid (ICS) (\>250 to ≤1000 µg/day fluticasone or equivalent) in combination with or without long acting beta agonist (LABA), insufficient control will be based on asthma control questionnaire (ACQ) score ≥1.5 points. Use of stable doses of other controller therapies according to GINA steps 3 and 4 (leukotriene modifiers, sustained release theophylline) are also acceptable, but NOT treatment with anti immunoglobulin E (IgE) antibodies within the past 6 months~* Stable but insufficiently controlled baseline conditions as documented by ACQ ≥1.5 at the screening and the baseline visits.~* Positive skin prick test (SPT) or radioallergosorbent test (RAST) to at least 1 aero-allergen during the screening period~* Forced expiratory volume in one second (FEV1)≥40 to ≤90% of predicted value~* Reversibility of airway obstruction as demonstrated by:~  * FEV1 improvement by \>12% , and~ * By ≥200 mL after inhaled β2-agonist (400 µg salbutamol or equivalent). If a subject does not meet reversibility criteria at the screening visit, reversibility may be retested once prior to run-in as long as the test is performed at least 5 days prior to the beginning of the run-in phase~Exclusion Criteria:~* Failure to meet at least 80% compliance with completion of asthma symptoms and medication diaries at the baseline visit, after initial instruction at the screening visit and where necessary additional training at the 2-weeks run-in visit. . An additional maximum 2-weeks training period may be added in such patients.~* Treatment or hospitalization for asthma exacerbation within past 2 months.~* Current use or use of systemic corticosteroids within past 2 months.~* Current smokers.~* Ex-smokers with a smoking history of \>10 pack years (1 package per day for 10 years).~* Pregnancy or female planning to become pregnant during the study period.~* Ongoing or planned specific immunotherapy (SIT) during the whole study period or SIT completed within the last 3 years.~* Treatment with IgE antibodies (Xolair®) within past 6 months.~* Use of investigational unapproved drugs within 30 days or within 5 half-lives of the investigational drug, whichever is longer, or planned use during the whole study period.~* Use of investigational biologics within the last 6 months.~* Previous participation in a clinical study with a virus like particle (VLP) Qb-based vaccine.~* Possible dependency of the patient on sponsor and/or investigator.~* Women of child bearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 7 weekly/biweekly injections of a placebo buffer
- CYT003 low dose (Type: EXPERIMENTAL): 7 weekly/biweekly injections of CYT003 low dose
- CYT003 medium dose (Type: EXPERIMENTAL): 7 weekly/biweekly injections of CYT003 medium dose
- CYT003 high dose (Type: EXPERIMENTAL): 7 weekly/biweekly injections of CYT003 high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).